Ibrutinib May Beat Back Leukemia – MedPage Today



Science Codex
Ibrutinib May Beat Back Leukemia
MedPage Today
Ibrutinib, an investigational inhibitor of Bruton's tyrosine kinase (BTK), induced long-lasting remissions in separate trials involving chronic lymphocytic leukemia (CLL) and mantle cell lymphoma, researchers reported. In the phase II mantle cell lymphoma trial, 
Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma NEWS.GNOM.ES
Drug shows surprising efficacy as treatment for chronic leukemia, mantle cell Science Codex
Ibrutinib Active in Refractory or Relapsed Mantle-Cell LymphomaDoctors Lounge
OncLive
all 15 news articles »

Read the entire article…